Antiplatelet Therapy in Myocardial Bridge: Insights From the RIALTO Registry
Journal of the American Heart Association · 15.07.2025 · 14 (14)
DOI: 10.1161/jaha.124.040513 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, erschienen am 15.07.2025. Verfasst von Renzo Laborante und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular and Thoracic Sciences Catholic University of the Sacred Heart Rome Italy. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Myocardial Bridging. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Myocardial bridge (MB) is a frequent coronary artery anomaly. The aims of this study are to describe the use of antiplatelet therapy (APT) in a cohort of patients with MB and assess its impact on ischemic and bleeding events.
Methods
The RIALTO (Myocardial Bridge Evaluation Towards Personalized Medicine) registry (ID: NCT05111418) is an ambispective multicenter observational registry, enrolling patients with a clinical indication to coronary angiography and evidence of MB. The present analysis included patients with MB without any preexisting indication for APT/anticoagulant therapy according to guidelines. Patients were categorized into 2 groups: single APT or no APT based on discharge prescriptions. The primary end point was the time to first occurrence of net adverse clinical events, defined as a composite of cardiovascular death, nonfatal myocardial infarction, unplanned or elective coronary angiography, ischemic cerebrovascular events, and any bleeding.
Results
Out of 486 enrolled patients with MB, 221 (mean age: 60 years, 66% male) were included in this analysis. One hundred and forty‐one patients (64%) received single APT. At a median follow‐up of 1661 days, patients with MB receiving single APT had a higher rate of net adverse clinical events (adjusted hazard ratio [aHR], 6.2; P =0.03), mainly driven by a higher rate of minor bleeding events (aHR, 10.58; P =0.02), with no difference regarding ischemic events. Results were consistent after 1:1 propensity‐score matching sensitivity analyses.
Conclusions
The prescription of single APT is common in patients with MB, and it seems to be associated with an increased risk of bleeding, in the absence of a beneficial effect on ischemic events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular and Thoracic Sciences Catholic University of the Sacred Heart Rome Italy.
- Department of Translational Medicine Università del Piemonte Orientale, Division of Cardiology, AOU Maggiore della Carità Novara Italy.
- Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Rome Italy.
- Maria Cecilia Hospital GVM Care & Research Ravenna Italy.
- Department of Medical-Surgical Sciences and Biotechnologies Sapienza University of Rome Latina Italy.
- Cardiothoracic and Vascular Department (DICATOV) IRCCS San Martino Hospital Genoa Italy.
ORCID-Profile: Renzo Laborante, Gaetano Rizzo, Francesco Canonico, Donato Antonio Paglianiti, Fabio Casamassima, Attilio Restivo, Francesco Burzotta, Carlo Trani, Cristina Aurigemma, Mattia Galli, Italo Porto, Gianluca Anastasia, Giuseppe Massimo Sangiorgi, Gianluca Massaro, Marta Cocco, Simone Biscaglia, Gianluca Campo, Filippo Crea, Giuseppe Patti, Domenico D'Amario
Zitieren
APA
Laborante, R., Ciliberti, G., Rizzo, G., Canonico, F., Paglianiti, D. A., Casamassima, F., Restivo, A., Cicchella, D., Burzotta, F., Trani, C., Aurigemma, C., Galli, M., Vergallo, R., Porto, I., Anastasia, G., Sangiorgi, G. M., Massaro, G., Cocco, M., Biscaglia, S., …, & RIALTO registry investigators (2025). Antiplatelet Therapy in Myocardial Bridge: Insights From the RIALTO Registry. Journal of the American Heart Association, 14(14). https://doi.org/10.1161/jaha.124.040513
Vancouver
Laborante R, Ciliberti G, Rizzo G, Canonico F, Paglianiti DA, Casamassima F, et al. Antiplatelet Therapy in Myocardial Bridge: Insights From the RIALTO Registry. Journal of the American Heart Association. 2025;14(14). doi:10.1161/jaha.124.040513
BibTeX
@article{Laborante2025,
author = {Laborante, Renzo and Ciliberti, Giuseppe and Rizzo, Gaetano and Canonico, Francesco and Paglianiti, Donato Antonio and Casamassima, Fabio and Restivo, Attilio and Cicchella, Domenico and Burzotta, Francesco and Trani, Carlo and Aurigemma, Cristina and Galli, Mattia and Vergallo, Rocco and Porto, Italo and Anastasia, Gianluca and Sangiorgi, Giuseppe Massimo and Massaro, Gianluca and Cocco, Marta and Biscaglia, Simone and Campo, Gianluca and Andreini, Daniele and Leone, Antonio Maria and Crea, Filippo and Patti, Giuseppe and D'Amario, Domenico and RIALTO registry investigators, RIALTO registry investigators},
title = {Antiplatelet Therapy in Myocardial Bridge: Insights From the RIALTO Registry},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {14},
doi = {10.1161/jaha.124.040513}
}
EUVIMED